Thermo Fisher expands ecosystem

Thermo Fisher Scientific spent April adding new pieces to the same lab stack: a new Polymerase Chain Reaction machine, new data ties, and fresh revenue targets. (newsroom.thermofisher.com) On April 16, the company launched the Applied Biosystems PowerFlex Thermal Cycler, a machine that repeatedly heats and cools samples so labs can copy DNA. Thermo Fisher said the instrument comes in 96-well and 3-by-32-well formats, with the smaller format able to run up to three protocols at once. (thermofisher.com) Thermo Fisher said PowerFlex is built for faster run times, tighter temperature control and broader plate compatibility, with a stated ramp rate of 7 degrees Celsius per second and temperature accuracy of plus or minus 0.15 degrees Celsius. The company lists the 96-well version at $11,700 on its catalog site. (thermofisher.com) Three days earlier, on April 13, Thermo Fisher’s PPD clinical research business said it would work with HealthVerity to expand real-world data capabilities, adding another data source for drug-development customers before first-quarter results. Thermo Fisher had also announced a biobank collaboration with PRECISE-SG100K Singapore on April 9. (newsroom.thermofisher.com) The strategy is to sell more than a standalone box. Thermo Fisher already spans instruments, lab software, consumables, contract research and manufacturing, and the new product and partnership announcements extend that reach deeper into how customers run experiments and clinical studies. (ir.thermofisher.com) That push got bigger on March 24, when Thermo Fisher closed its $8.875 billion acquisition of Clario Holdings, which provides endpoint data systems for clinical trials. Thermo Fisher said Clario’s business will sit inside its Laboratory Products and Biopharma Services segment and is expected to contribute $0.45 in adjusted earnings per share in the first year after closing. (ir.thermofisher.com) Clario’s platform has supported about 70% of novel drug approvals by the Food and Drug Administration and European Medicines Agency over the past decade, according to Thermo Fisher. The company said it expects roughly $175 million of adjusted operating income from synergies by year five, with most of that tied to revenue synergies. (ir.thermofisher.com) Thermo Fisher enters its April 23 earnings call after reporting $44.56 billion in 2025 revenue, up 4% from 2024, and after telling investors in January that product launches and commercial execution were driving share gains. Third-party earnings calendars and coverage ahead of the call showed 2026 revenue guidance of $46.3 billion to $47.2 billion, including Clario, which points to roughly 4% to 6% reported growth. (ir.thermofisher.com) (marketbeat.com) (genomeweb.com) Thermo Fisher has been building the same connected-lab pitch elsewhere this year. In January, it announced an artificial intelligence collaboration with NVIDIA aimed at linking instruments, laboratory infrastructure and data to automation and analysis tools at scale. (ir.thermofisher.com) The immediate test comes Thursday, April 23, when Thermo Fisher reports first-quarter 2026 results before the market opens. By then, investors will be able to judge whether April’s product and partnership burst is translating into the faster, more connected workflows the company has been selling. (ir.thermofisher.com)